Skip to main content
SpringerLink
Log in

Diagnostic Values of Immunohistochemistry in Bladder Cancer

  • Chapter
  • First Online:
Urinary Bladder Pathology

  • 767 Accesses

Abstract

Diagnosis and classification of urothelial carcinoma are usually straightforward based on gross and routine microscopic examination. However, immunohistochemistry can be very helpful in several situations. In this chapter we will discuss the general consideration and value of immunohistochemistry in some special diagnosis scenarios including distinction of urothelial reactive atypia from flat urothelial carcinoma in situ, assessment of the depth of invasion, establishment of urothelial lineage including differentiating urothelial carcinoma from secondarily tumor involving the bladder, differential diagnosis of spindle cell lesions, and therapeutic and prognosis prediction. Commonly used immunohistochemistry markers, panel’s selection, and immunohistochemistry profiles in the differential diagnosis of major urinary bladder lesions will be provided.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Moch H, Humphrey PA, Ulbright TM, Reuter VE. WHO classification of tumors of the urinary system and male genital organs. 4th ed. Lyon: IARC Press; 2016.

    Google Scholar 

  2. McKenney JK, Desai S, Cohen C, Amin MB. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium. An analysis of cytokeratin 20, P53, and CD44 antigens. Am J Surg Pathol. 2001;25(8):1074–8.

    Article  CAS  PubMed  Google Scholar 

  3. Mallofre C, Castillo M, Morente V, Sole M. Immunohistochemical expression of CK20, P53, and Ki-67 as objective markers of urothelial dysplasia. Mod Pathol. 2003;16:187–91.

    Article  PubMed  Google Scholar 

  4. Kunju LP, Lee CT, Montie J, Shah RB. Utility of cytokeratin 20 and Ki-67 as objective markers of urothelial dysplasia. Pathol Int. 2005;55(5):248–54.

    Article  PubMed  Google Scholar 

  5. Alston ELJ, Zynger DL. Does the addition of AMACR to CK20 help to diagnose challenging cases of urothelial carcinoma in situ? Diagn Pathol. 2019;14(1):91.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Neal DJ, Amin MB, Smith SC. CK20 versus AMACR and p53 immunostains in evaluation of Urothelial Carcinoma in Situ and Reactive Atypia. Diagn Pathol. 2020;15:61. https://doi.org/10.1186/s13000-020-00984-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Aron M, Luthringer DJ, Mckenney JK, Hansel DE, Westfall DE, Parakh R, et al. Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia. Am J Surg Pathol. 2013;37(12):1815–23.

    Article  PubMed  Google Scholar 

  8. Brent Arville, Emily O’Rourke, Fai Chung, Mahul Amin, Shikha Bose. Evaluation of a triple combination of cytokeratin 20, p53 and CD44 for improving detection of urothelial carcinoma in urine cytology specimens. Cytojournal. 2013, 10:25.

    Google Scholar 

  9. Paner GP, Shen SS, Lapetino S, Venkataraman G, Barkan GA, Quek ML, Ro JY. Amin diagnostic utility of antibody to smoothelin in the distinction of muscularis propria from muscularis mucosae of the urinary bladder: a potential ancillary tool in the pathologic staging of invasive urothelial carcinoma. Am J Surg Pathol. 2009;33(1):91–8.

    Article  PubMed  Google Scholar 

  10. Bovio IM, Al-Quran SZ, Rosser CJ, Algood CB, Drew PA, Allan RW. Smoothelin immunohistochemistry is a useful adjunct for assessing muscularis propria invasion in bladder carcinoma. Histopathology. 2010;56(7):951–6.

    Article  PubMed  Google Scholar 

  11. Hansel DE, Paner GP, Nese N, Amin MB. Limited smoothelin expression the muscularis propria: validation in bladder diverticula. Human Pathol. 2011;42(11):1770–6.

    Article  Google Scholar 

  12. Miyamoto H, Sharma RB, Illei PB, Epstein JI. Pitfalls in the use of smoothelin to identify muscularis propria invasion by urothelial carcinoma. Am J Surg Pathol. 2010;34(3):418–22.

    Article  PubMed  Google Scholar 

  13. Liu H, Shi J, Wilkerson ML, Lin F. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas. Am J Clin Pathol. 2012;138(1):57–64.

    Article  PubMed  Google Scholar 

  14. Verduin L, Mentrikoski MJ, Heitz CT, Wick MR. The utility of GATA3 in the diagnosis of urothelial carcinoma with variant morphologic patterns. Appl Immunohistochem Mol Morphol. 2016;24(7):509–13.

    Article  CAS  PubMed  Google Scholar 

  15. Clark BZ, Beriwal S, Dabbs DJ, Bhargava R. Semiquantitative GATA-3 immunoreactivity in breast, bladder, gynecologic tract, and other cytokeratin 7-positive carcinomas. Am J Clin Pathol. 2014;142(1):64–71.

    Article  PubMed  Google Scholar 

  16. Amin MB, Trpkov K, Lopez-Beltran A, Grignon D, et al. Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol. 2014;38(8):e20–34.

    Article  PubMed  Google Scholar 

  17. Hoang L, Tacha DE, Qi W, Yu C, Bremer RE, Chu J, Haas TS, Cheng L. A newly developed uroplakin II antibody with increased sensitivity in urothelial carcinoma of the bladder. Arch Pathol Lab Med. 2014;138:943–9.

    Article  CAS  PubMed  Google Scholar 

  18. Chuang AY, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol. 2007;31(8):1246–55.

    Article  PubMed  Google Scholar 

  19. Lin X, Zhu B, Villa C, Zhong M, Kundu S, Rohan S, Yang XJ. The utility of p63, p40, and GATA-binding protein 3 immunohistochemistry in diagnosing micropapillary urothelial carcinoma. Hum Pathol. 2014;45(9):1824–9.

    Article  CAS  PubMed  Google Scholar 

  20. Higgins JPT, Kaygusuz G, Wang L, et al. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol. 2007;31:673–80.

    Article  PubMed  Google Scholar 

  21. Suryavanshi M, Sanz-Ortega J, Sirohi D, et al. S100P as a marker for urothelial histogenesis: a critical review and comparison with novel and traditional urothelial immunohistochemical markers. Adv Anat Pathol. 2017;24(3):151–60.

    Article  CAS  PubMed  Google Scholar 

  22. Paner GP, Luthringer DJ, Amin MB. Best practice in diagnostic immunohistochemistry: prostate carcinoma and its mimics in needle core biopsies. Arch Pathol Lab Med. 2008;132(9):1388–96. Review

    Article  PubMed  Google Scholar 

  23. Mai KT, Collins JP, Veinot JP. Prostatic adenocarcinoma with urothelial (transitional cell) carcinoma features. Appl Immunohistochem Mol Morphol. 2002;10(3):231–6.

    Article  PubMed  Google Scholar 

  24. Chuang AY, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol. 2007;31(8):1246–55.

    Article  PubMed  Google Scholar 

  25. Genega EM, Hutchinson B, Reuter VE, Gaudin PB. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma. Mod Pathol. 2000;13(11):1186–91.

    Article  CAS  PubMed  Google Scholar 

  26. Parker DC, Folpe AL, Bell J, et al. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas. Am J Surg Pathol. 2003;27(1):1–10.

    Article  PubMed  Google Scholar 

  27. GurelB ATZ, Montgomery EA, et al. NKX3.1 as a marker of prostatic origin in metastatic tumors. Am J Surg Pathol. 2010;34(8):1097–105.

    Article  Google Scholar 

  28. Kalos M, Askaa J, Hylander BL, et al. Prostein expression is highly restricted to normal and malignant prostate tissues. Prostate. 2004;60(3):246–56.

    Article  CAS  PubMed  Google Scholar 

  29. Oh WJ, Chungm AM, Kim JS, et al. Differential immunohistochemical profiles for distinguishing prostate carcinoma and urothelial carcinoma. J Pathol Transl Med. 2016;50(5):345–54.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Epstein JI, Egevad L, Humphrey PA, Montironi R. Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol. 2014;38(8):e6–e19.

    Article  PubMed  Google Scholar 

  31. Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol. 2002;117(3):471–7.

    Article  PubMed  Google Scholar 

  32. Mhawech P, Uchida T, Pelte MF. Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma. Hum Pathol. 2002;33(11):1136–40.

    Article  PubMed  Google Scholar 

  33. Varma M, Morgan M, Jasani B, Tamboli P, Amin MB. Polyclonal anti-PSA is more sensitive but less specific than monoclonal anti-PSA: implications for diagnostic prostatic pathology. Am J Clin Pathol. 2002;118(2):202–7.

    Article  CAS  PubMed  Google Scholar 

  34. Huang H, Guma SR, Melamed J, Zhou M, Lee P, Deng FM. NKX3.1 and PSMA are sensitive diagnostic markers for prostatic carcinoma in bone metastasis after decalcification of specimens. Am J Clin Exp Urol. 2018;6(5):182–8.

    PubMed  PubMed Central  Google Scholar 

  35. Shah RB. Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management. Adv Anat Pathol. 2013;20(2):117–24.

    Article  CAS  PubMed  Google Scholar 

  36. Brooks JD, Wei W, Hawley S, et al. Evaluation of ERG and SPINK1 by Immunohistochemical staining and Clinicopathological outcomes in a multi-institutional radical prostatectomy cohort of 1067 patients. PLoS One. 2015;10(7):e0132343.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  37. Parsons JK, Gage WR, Nelson WG, De Marzo AM. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology. 2001;58(4):619–24.

    Article  CAS  PubMed  Google Scholar 

  38. Mazal PR, et al. Derivation of nephrogenic adenomas from renal tubular cells in kidney-transplant recipients. N Engl J Med. 2002;347(9):653–9.

    Article  PubMed  Google Scholar 

  39. Gupta A, Wang HL, Policarpio-Nicolas ML, et al. Expression of alpha-methylacyl-coenzyme a racemase in nephrogenic adenoma. Am J Surg Pathol. 2004;28(9):1224–9.

    Article  PubMed  Google Scholar 

  40. Tong GX, Melamed J, Mansukhani M, et al. PAX2: a reliable marker for nephrogenic adenoma. Mod Pathol. 2006;19(3):356–63.

    Article  CAS  PubMed  Google Scholar 

  41. Piña-Oviedo S, Shen SS, Truong LD, Ayala AG, Ro JY. Flat pattern of nephrogenic adenoma: previously unrecognized pattern unveiled using PAX2 and PAX8 immunohistochemistry. Mod Pathol. 2013;26(6):792–8.

    Article  PubMed  CAS  Google Scholar 

  42. Brimo F, Herawi M, Sharma R, Netto GJ, Epstein JI, Illei PB. Hepatocyte nuclear factor-1β expression in clear cell adenocarcinomas of the bladder and urethra: diagnostic utility and implications for histogenesis. Hum Pathol. 2011;42(11):1613–9.

    Article  CAS  PubMed  Google Scholar 

  43. Malpica A, Ro JY, Troncoso P, Ordoñez NG, Amin MB, Ayala AG. Nephrogenic adenoma of the prostatic urethra involving the prostate gland: a clinicopathologic and immunohistochemical study of eight cases. Hum Pathol. 1994;25(4):390–5.

    Article  CAS  PubMed  Google Scholar 

  44. Wang HL, Lu DW, Yerian LM, et al. Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Am J Surg Pathol. 2001;25(11):1380–7.

    Article  CAS  PubMed  Google Scholar 

  45. Rao Q, Williamson SR, Lopez-Beltran A, et al. Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: extended immunohistochemical profiles emphasizing novel markers. Mod Pathol. 2013;26(5):725–32.

    Article  CAS  PubMed  Google Scholar 

  46. Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25(2):152–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Rijnders M, van der Veldt AAM, Zuiverloon TCM, et al. PD-L1 antibody comparison in Urothelial carcinoma. Eur Urol. 2019;75(3):538–40.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lab Medicine and Pathology, Mayo Clinic Florida, Jacksonville, FL, USA

    Qihui “Jim” Zhai

  2. Department of Pathology, New York University Langone Health, New York, NY, USA

    Fang-Ming Deng

Authors
  1. Qihui “Jim” Zhai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fang-Ming Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fang-Ming Deng .

Editor information

Editors and Affiliations

  1. Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, USA

    Haijun Zhou

  2. Department of Pathology, MD Anderson Cancer Center, Houston, TX, USA

    Charles C. Guo

  3. Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, USA

    Jae Y. Ro

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Zhai, Q.“., Deng, FM. (2021). Diagnostic Values of Immunohistochemistry in Bladder Cancer. In: Zhou, H., Guo, C.C., Ro, J.Y. (eds) Urinary Bladder Pathology. Springer, Cham. https://doi.org/10.1007/978-3-030-71509-0_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-71509-0_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-71508-3

  • Online ISBN: 978-3-030-71509-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation